NKTR
Nektar’s 40% drop yesterday was an extreme over-reaction: What I’m doing now
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Stock or options, Nektar needs some understanding and patience now
It hasn't exactly been a stellar couple of months for shares and options on Nektar Therapeutics (NKTR). The stock is down 23.1% since it hit a high of $108.44 on March 8. The August 17, 2018 call options with a strike of $90 I bought on February 25, 2018 are now down...
Positive catalysts are intact for Nektar Therapeutics
Shares of biotech rocket Nektar Therapeutics (NKTR) are down 23.25% since they traded at $106.91 on March 21, 2018. I can't find evidence that the positive catalysts that led me to recommend the stock for my Jubak Picks portfolio and the options for my Volatility...
Nektar blows away revenue projections, gives very positive guidance on drug pipeline
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...
Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate still in trials and that has shown the ability to extend the range of Bristol-Myers Opdivo
Nektar soars today on J.P. Morgan healthcare conference
Anybody still think that conferences, especially biotech conferences, don’t move stock prices? Shares of Nektar Therapeutics (NKTR) are up 7.65% today to $61.79 as of noon New York time on the company’s appearance at this week’s J.P. Morgan biotech conference. The slides from the company’s presentation today are in circulation but CEO Howard Robin doesn’t actually present until 2 p.m. New York time today.
On the second day of Christmas my stock pick for 2018 is Nektar Therapeutics–and two-turtle doves
No point in hoping that Nektar Therapeutics (NKTR) will match this year's gain of 364% as of the close on December 18. But I think the stock could easily climb another 30% or more in 2018 as the company de-risks its very promising drug candidates in the opioid and...
Nektar soared today on cancer drug data–but remember that new opioid? That’s why I say hold even after this run
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Nektar soars–again–on oncology drug data
Shares of Nektar Therapeutics (NKTR) are up another 16% this morning to $37.89 as of noon New York time on data presented this weekend at the annual meeting of the Society for Immunotherapy of Cancer from an early trial of Nektar's NKTR-214. The data looked at the...
Nektar rockets ahead, options in my Volatility Portfolio head for orbit
On the evening of October 31 I wrote that a decision onwhat to do with the Netkar Therapeutics options (NKTR180119C00022000)--the January 19, 2018 call at $22--that I added to my Volatility Portfolio back on May 16, 2017 at a price of $2.64 (the closing options price...
